ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Smaller-scale trades involved Pacific Biosciences of California Inc (NASDAQ: PACB) and 10X Genomics Inc (NASDAQ: TXG ), with ARK purchasing 194,298 and 18,177 shares respectively, totaling $213,727 ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Giovinazzo is a Non-Executive Chairman at XORTX Therapeutics, Inc., an Executive Chairman at Kalgene Pharmaceuticals, Inc. and a Member at Institute of Corporate Directors. He is on the Board of ...

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viking Therapeutics (NASDAQ ... to the same period in 2024," the company said in a statement. The company's stock is down about 1% after the bell.

VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics stock was down 1.12% after hours at $25.50 on Wednesday.

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Cardiol Therapeutics CRDL is among the few companies evaluating an investigational cannabidiol (CBD) drug in late-stage development. This Canada-based company is developing an oral CBD-based ...

With the firm’s Outperform rating, William Blair signals its confidence in Context Therapeutics’ potential to succeed within this innovative space. The stock has experienced significant volatility, ...